Barclays PLC Sells 509,134 Shares of Grifols, S.A. (NASDAQ:GRFS)

Barclays PLC decreased its position in Grifols, S.A. (NASDAQ:GRFS) by 85.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 83,418 shares of the biotechnology company’s stock after selling 509,134 shares during the period. Barclays PLC’s holdings in Grifols were worth $621,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 1,527 shares during the period. Charles Schwab Investment Management Inc. raised its position in Grifols by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Grifols by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company’s stock worth $192,000 after buying an additional 2,403 shares during the period. R Squared Ltd bought a new stake in shares of Grifols in the 4th quarter worth approximately $28,000. Finally, HighTower Advisors LLC increased its stake in shares of Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 3,936 shares during the period.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.32 on Thursday. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96. The stock has a market capitalization of $5.03 billion, a P/E ratio of 6.26 and a beta of 0.44. The company’s 50-day moving average is $7.39 and its 200 day moving average is $7.68. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.